Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: Therapeutic implications

Frontiers in Physiology

Volumn 9, Issue FEB, 2018, Pages

  Sharma, Arpeeta ^a   Tate, Mitchel ^a   Mathew, Geetha ^b   Vince, James E ^c,d   Ritchie, Rebecca H ^a   De Haan, Judy B ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Diabetic atherosclerosis; Diabetic cardiomyopathy; Diabetic complications; Diabetic nephropathy; Inflammation; Inflammatory cytokines; NLRP3 inflammasome; Oxidative stress

Indexed keywords

CANAKINUMAB; CARRIER PROTEINS AND BINDING PROTEINS; CHOLESTEROL; CRYOPYRIN; GLIBENCLAMIDE; GLUCOSE; GLUCOSE TRANSPORTER 4; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 1BETA CONVERTING ENZYME; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROTEIN NLRP1; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ATHEROSCLEROSIS; BIOACCUMULATION; BLOOD VESSEL INJURY; CELL DEATH; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HEART INJURY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN DOMAIN; PYROPTOSIS; REVIEW;

EID: 85042221426     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2018.00114     Document Type: Review

References (135)

1. Abderrazak, A., Couchie, D., Mahmood, D. F., Elhage, R., Vindis, C., Laffargue, M., et al. (2015). Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation 131, 1061-1070. doi: 10.1161/CIRCULATIONAHA.114.013730
2. Aglietti, R. A., Estevez, A., Gupta, A., Ramirez, M. G., Liu, P. S., Kayagaki, N., et al. (2016). GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc. Natl. Acad. Sci. U.S.A. 113, 7858-7863. doi: 10.1073/pnas.1607769113
3. Ashcroft, F. M. (2005). ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 115, 2047-2058. doi: 10.1172/JCI25495
4. Bae, H. R., Kim, D. H., Park, M. H., Lee, B., Kim, M. J., Lee, E. K., et al. (2016). beta-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget 7, 66444-66454. doi: 10.18632/oncotarget.12119
5. Baker, P. J., De Nardo, D., Moghaddas, F., Tran, L. S., Bachem, A., Nguyen, T., et al. (2017). Posttranslational modification as a critical determinant of cytoplasmic innate immune recognition. Physiol. Rev. 97, 1165-1209. doi: 10.1152/physrev.00026.2016
6. Barajas, B., Che, N., Yin, F., Rowshanrad, A., Orozco, L. D., Gong, K. W., et al. (2011). NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. Arterioscler. Thromb. Vasc. Biol. 31, 58-66. doi: 10.1161/ATVBAHA.110.210906
7. Bayeva, M., Sawicki, K. T., and Ardehali, H. (2013). Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J. Am. Heart Assoc. 2:e000433. doi: 10.1161/JAHA.113.000433
8. Benetti, E., Mastrocola, R., Vitarelli, G., Cutrin, J. C., Nigro, D., Chiazza, F., et al. (2016). Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J. Pharmacol. Exp. Ther. 359, 45-53. doi: 10.1124/jpet.116.235069
9. Bhat, O. M., Kumar, P. U., Giridharan, N. V., Kaul, D., Kumar, M. J., and Dhawan, V. (2015). Interleukin-18-induced atherosclerosis involves CD36 and NF-kappaB crosstalk in Apo E-/-mice. J. Cardiol. 66, 28-35. doi: 10.1016/j.jjcc.2014.10.012
10. Birnbaum, Y., Bajaj, M., Qian, J., and Ye, Y. (2016). Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care 4:e000227. doi: 10.1136/bmjdrc-2016-000227
11. Bracey, N. A., Gershkovich, B., Chun, J., Vilaysane, A., Meijndert, H. C., Wright, J. R. Jr., et al. (2014). Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J. Biol. Chem. 289, 19571-19584. doi: 10.1074/jbc. M114.550624
12. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820. doi: 10.1038/414813a
13. Butts, B., Gary, R. A., Dunbar, S. B., and Butler, J. (2015). The importance of NLRP3 inflammasome in heart failure. J. Card. Fail. 21, 586-593. doi: 10.1016/j.cardfail.2015.04.014
14. Cai, J., Lu, S., Yao, Z., Deng, Y. P., Zhang, L. D., Yu, J. W., et al. (2014). Glibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic mice. Cardiovasc. Diabetol. 13:106. doi: 10.1186/s12933-014-0106-y
15. Cai, X., Chen, J., Xu, H., Liu, S., Jiang, Q. X., Halfmann, R., et al. (2014). Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell. 156, 1207-1222. doi: 10.1016/j.cell.2014.01.063
16. Canna, S. W., de Jesus, A. A., Gouni, S., Brooks, S. R., Marrero, B., Liu, Y., et al. (2014). An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140-1146. doi: 10.1038/ng.3089
17. Chen, K. W., Gross, C. J., Sotomayor, F. V., Stacey, K. J., Tschopp, J., Sweet, M. J., et al. (2014). The neutrophil NLRC4 inflammasome selectively promotes IL-1beta maturation without pyroptosis during acute Salmonella challenge. Cell Rep. 8, 570-582. doi: 10.1016/j.celrep.2014.06.028
18. Conos, S. A., Lawlor, K. E., Vaux, D. L., Vince, J. E., and Lindqvist, L. M. (2016). Cell death is not essential for caspase-1-mediated interleukin-1beta activation and secretion. Cell Death Differ. 23, 1827-1838. doi: 10.1038/cdd.2016.69
19. Conos, S. A., Chen, K. W., De Nardo, D., Hara, H., Whitehead, L., Nunez, G., et al. (2017). Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc. Natl. Acad. Sci. U.S.A. 114, E961-E969. doi: 10.1073/pnas.1613305114
20. de Haan, J. B., and Cooper, M. E. (2011). Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. Front. Biosci. (Schol. Ed). 3, 709-729. doi: 10.2741/s182
21. De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., and Minutolo, R. (2014). Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am. J. Kidney Dis. 64, 16-24. doi: 10.1053/j.ajkd.2014.02.010
22. Di Marco, E., Gray, S. P., Chew, P., Kennedy, K., Cooper, M. E., Schmidt, H. H., et al. (2016). Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/-mice. Clin. Sci. 130, 1363-1374. doi: 10.1042/CS20160249
23. Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., et al. (2016). Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111-116. doi: 10.1038/nature18590
24. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., et al. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361. doi: 10.1038/nature08938
25. Elhage, R., Jawien, J., Rudling, M., Ljunggren, H. G., Takeda, K., Akira, S., et al. (2003). Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234-240. doi: 10.1016/S0008-6363(03)00343-2
26. Engelbertsen, D., To, F., Duner, P., Kotova, O., Soderberg, I., Alm, R., et al. (2012). Increased inflammation in atherosclerotic lesions of diabetic Akita-LDLr(-)/(-) mice compared to nondiabetic LDLr(-)/(-) mice. Exp. Diabetes Res. 2012:176162. doi: 10.1155/2012/176162
27. Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., and Paquot, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 105, 141-150. doi: 10.1016/j.diabres.2014.04.006
28. Feng, H., Gu, J., Gou, F., Huang, W., Gao, C., Chen, G., et al. (2016). High glucose and lipopolysaccharide prime NLRP3 Inflammasome via ROS/TXNIP pathway in mesangial cells. J. Diabetes Res. 2016:6973175. doi: 10.1155/2016/6973175
29. Fischer, C. P., Perstrup, L. B., Berntsen, A., Eskildsen, P., and Pedersen, B. K. (2005). Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin. Immunol. 117, 152-160. doi: 10.1016/j.clim.2005.07.008
30. Franklin, B. S., Bossaller, L., De Nardo, D., Ratter, J. M., Stutz, A., Engels, G., et al. (2014). The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat. Immunol. 15, 727-737. doi: 10.1038/ni.2913
31. Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A. T., Kisielow, J., et al. (2011). Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 41, 2040-2051. doi: 10.1002/eji.201041316
32. Fu, Y., Wu, N., and Zhao, D. (2017). Function of NLRP3 in the pathogenesis and development of diabetic nephropathy. Med. Sci. Monit. 23, 3878-3884. doi: 10.12659/MSM.903269
33. Gage, J., Hasu, M., Thabet, M., and Whitman, S. C. (2012). Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. Can. J. Cardiol. 28, 222-229. doi: 10.1016/j.cjca.2011.10.013
34. Garstkiewicz, M., Strittmatter, G. E., Grossi, S., Sand, J., Fenini, G., Werner, S., et al. (2017). Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. Eur. J. Immunol. 47, 806-817. doi: 10.1002/eji.201646665
35. Gray, S. P., and Jandeleit-Dahm, K. A. (2015). The role of NADPH oxidase in vascular disease-hypertension, atherosclerosis & stroke. Curr. Pharm. Des. 21, 5933-5944. doi: 10.2174/1381612821666151029112302
36. Greaney, A. J., Maier, N. K., Leppla, S. H., and Moayeri, M. (2016). Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J. Leukoc. Biol. 99, 189-199. doi: 10.1189/jlb.3A0415-155RR
37. Guo, H., Callaway, J. B., and Ting, J. P. (2015). Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677-687. doi: 10.1038/nm.3893
38. Gutierrez, K. D., Davis, M. A., Daniels, B. P., Olsen, T. M., Ralli-Jain, P., Tait, S. W., et al. (2017). MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1beta Independently of Gasdermin-D. J. Immunol. 198, 2156-2164. doi: 10.4049/jimmunol.1601757
39. He, Y., Zeng, M. Y., Yang, D., Motro, B., and Nunez, G. (2016). NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354-357. doi: 10.1038/nature16959
40. Hendrikx, T., Jeurissen, M. L., van Gorp, P. J., Gijbels, M. J., Walenbergh, S. M., Houben, T., et al. (2015). Bone marrow-specific caspase-1/11 deficiency inhibits atherosclerosis development in Ldlr(-/-) mice. FEBS J. 282, 2327-2338. doi: 10.1111/febs.13279
41. Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature 444, 860-867. doi: 10.1038/nature05485
42. Hung, J., McQuillan, B. M., Chapman, C. M., Thompson, P. L., and Beilby, J. P. (2005). Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 25, 1268-1273. doi: 10.1161/01.ATV.0000163843.70369.12
43. Jia, G., Whaley-Connell, A., and Sowers, J. R. (2018). Diabetic cardiomyopathy: a hyperglycaemia-and insulin-resistance-induced heart disease. Diabetologia 61, 21-28. doi: 10.1007/s00125-017-4390-4
44. Jia, G., DeMarco, V. G., and Sowers, J. R. (2016). Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat. Rev. Endocrinol. 12, 144-153. doi: 10.1038/nrendo.2015.216
45. Kaplanski, G. (2018). Interleukin-18: biological properties and role in disease pathogenesis. Immunol. Rev. 281, 138-153. doi: 10.1111/imr.12616
46. Kayagaki, N., Stowe, I. B., Lee, B. L., O'Rourke, K., Anderson, K., Warming, S., et al. (2015). Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666-671. doi: 10.1038/nature15541
47. Khaleeli, E., Peters, S. R., Bobrowsky, K., Oudiz, R. J., Ko, J. Y., and Budoff, M. J. (2001). Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: implications for management. Am. Heart J. 141, 637-644. doi: 10.1067/mhj.2001.113224
48. Kim, S. M., Lee, S. H., Kim, Y. G., Kim, S. Y., Seo, J. W., Choi, Y. W., et al. (2015). Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 308, F993-F1003. doi: 10.1152/ajprenal.00637.2014
49. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., et al. (2003). Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656-660. doi: 10.1161/01.ATV.0000064374.15232.C3
50. Klen, J., Goricar, K., Janez, A., and Dolzan, V. (2015). NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients. J. Diabetes Res. 2015:616747. doi: 10.1155/2015/616747
51. Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., et al. (2016). Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 7:11624. doi: 10.1038/ncomms11624
52. Koh, G. C., Maude, R. R., Schreiber, M. F., Limmathurotsakul, D., Wiersinga, W. J., Wuthiekanun, V., et al. (2011). Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin. Infect. Dis. 52, 717-725. doi: 10.1093/cid/ciq192
53. Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., et al. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61-70. doi: 10.1083/jcb.200903124
54. Latz, E., Xiao, T. S., and Stutz, A. (2013). Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397-411. doi: 10.1038/nri3452
55. Lawlor, K. E., and Vince, J. E. (2014). Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria? Biochim. Biophys. Acta. 1840, 1433-1440. doi: 10.1016/j.bbagen.2013.08.014
56. Lee, H. M., Kim, J. J., Kim, H. J., Shong, M., Ku, B. J., and Jo, E. K. (2013). Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194-204. doi: 10.2337/db12-0420
57. Leng, W., Ouyang, X., Lei, X., Wu, M., Chen, L., Wu, Q., et al. (2016). The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/-Mice. Mediators Inflamm. 2016:6305735. doi: 10.1155/2016/6305735
58. Li, Y., Xu, S., Jiang, B., Cohen, R. A., and Zang, M. (2013). Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PLoS ONE 8:e67532. doi: 10.1371/journal.pone.0067532
59. Lin, J., Shou, X., Mao, X., Dong, J., Mohabeer, N., Kushwaha, K. K., et al. (2013). Oxidized low density lipoprotein induced caspase-1 mediated pyroptotic cell death in macrophages: implication in lesion instability? PLoS ONE 8:e62148. doi: 10.1371/journal.pone.0062148
60. Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., et al. (2016). Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153-158. doi: 10.1038/nature18629
61. Liu, X., Zhang, X., Ding, Y., Zhou, W., Tao, L., Lu, P., et al. (2017). Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming. Antioxid. Redox Signal. 26, 28-43. doi: 10.1089/ars.2015.6615
62. Lopez-Castejon, G., and Brough, D. (2011). Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 22, 189-195. doi: 10.1016/j.cytogfr.2011.10.001
63. Lu, A., Magupalli, V. G., Ruan, J., Yin, Q., Atianand, M. K., Vos, M. R., et al. (2014). Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193-1206. doi: 10.1016/j.cell.2014.02.008
64. Lu, M., Yin, N., Liu, W., Cui, X., Chen, S., and Wang, E. (2017). curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling. Biomed Res. Int. 2017:1516985. doi: 10.1155/2017/1516985
65. Luo, B., Huang, F., Liu, Y., Liang, Y., Wei, Z., Ke, H., et al. (2017). NLRP3 inflammasome as a molecular marker in diabetic cardiomyopathy. Front. Physiol. 8:519. doi: 10.3389/fphys.2017.00519
66. Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., et al. (2014a). NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9:e104771. doi: 10.1371/journal.pone.0104771
67. Luo, B., Li, B., Wang, W., Liu, X., Liu, X., Xia, Y., et al. (2014b). Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther. 28, 33-43. doi: 10.1007/s10557-013-6498-1
68. Manthiram, K., Zhou, Q., Aksentijevich, I., and Kastner, D. L. (2017). The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat. Immunol. 18, 832-842. doi: 10.1038/ni.3777
69. Marchetti, C., Chojnacki, J., Toldo, S., Mezzaroma, E., Tranchida, N., Rose, S. W., et al. (2014). A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J. Cardiovasc. Pharmacol. 63, 316-322. doi: 10.1097/FJC.0000000000000053
70. Marchioli, R., Schweiger, C., Levantesi, G., Tavazzi, L., and Valagussa, F. (2001). Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36(Suppl.), S53-S63. doi: 10.1007/s11745-001-0683-y
71. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241. doi: 10.1038/nature04516
72. Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., et al. (2010). Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11, 897-904. doi: 10.1038/ni.1935
73. Menu, P., and Vince, J. E. (2011). The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin. Exp. Immunol. 166, 1-15. doi: 10.1111/j.1365-2249.2011.04440.x
74. Menu, P., Pellegrin, M., Aubert, J. F., Bouzourene, K., Tardivel, A., Mazzolai, L., et al. (2011). Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis. 2:e137. doi: 10.1038/cddis.2011.18
75. Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., et al. (2011). The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl. Acad. Sci. U.S.A. 108, 19725-19730. doi: 10.1073/pnas.1108586108
76. Monnerat, G., Alarcon, M. L., Vasconcellos, L. R., Hochman-Mendez, C., Brasil, G., Bassani, R. A., et al. (2016). Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7:13344. doi: 10.1038/ncomms13344
77. Muñoz-Planillo, R., Kuffa, P., Martinez-Colon, G., Smith, B. L., Rajendiran, T. M., and Nunez, G. (2013). K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153. doi: 10.1016/j.immuni.2013.05.016
78. Murphy, A. J., Kraakman, M. J., Kammoun, H. L., Dragoljevic, D., Lee, M. K., Lawlor, K. E., et al. (2016). IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab. 23, 155-164. doi: 10.1016/j.cmet.2015.09.024
79. Netea, M. G., Joosten, L. A., Lewis, E., Jensen, D. R., Voshol, P. J., Kullberg, B. J., et al. (2006). Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 12, 650-656. doi: 10.1038/nm1415
80. Ozaki, E., Campbell, M., and Doyle, S. L. (2015). Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J. Inflamm. Res. 8, 15-27. doi: 10.2147/JIR.S51250
81. Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., et al. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 8:e54442. doi: 10.1371/journal.pone.0054442
82. Paramel Varghese, G., Folkersen, L., Strawbridge, R. J., Halvorsen, B., Yndestad, A., Ranheim, T., et al. (2016). NLRP3 inflammasome expression and activation in human atherosclerosis. J. Am. Heart Assoc. 5:e003031. doi: 10.1161/JAHA.115.003031
83. Paterniti, I., Di Paola, R., Campolo, M., Siracusa, R., Cordaro, M., Bruschetta, G., et al. (2015). Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 769, 313-323. doi: 10.1016/j.ejphar.2015.11.035
84. Pétrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., and Tschopp, J. (2007). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589. doi: 10.1038/sj.cdd.4402195
85. Petrov, V. V., Fagard, R. H., and Lijnen, P. J. (2002). Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39, 258-263. doi: 10.1161/hy0202.103268
86. Rader, D. J. (2012). IL-1 and atherosclerosis: a murine twist to an evolving human story. J. Clin. Invest. 122, 27-30. doi: 10.1172/JCI61163
87. Rajesh, M., Batkai, S., Kechrid, M., Mukhopadhyay, P., Lee, W. S., Horvath, B., et al. (2012). Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61, 716-727. doi: 10.2337/db11-0477
88. Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., et al. (2017a). Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119-1131. doi: 10.1056/NEJMoa1707914
89. Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., et al. (2017b). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833-1842. doi: 10.1016/S0140-6736(17)32247-X
90. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W., and Grishman, A. (1972). New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595-602. doi: 10.1016/0002-9149(72)90595-4
91. Ruiz, S., Pergola, P. E., Zager, R. A., and Vaziri, N. D. (2013). Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83, 1029-1041. doi: 10.1038/ki.2012.439
92. Ruscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V., Berardicurti, O., Carubbi, F., et al. (2015). Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1beta via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin. Exp. Immunol. 182, 35-44. doi: 10.1111/cei.12667
93. Sakai, N., and Wada, T. (2015). Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int. 87, 12-14. doi: 10.1038/ki.2014.322
94. Sborgi, L., Ruhl, S., Mulvihill, E., Pipercevic, J., Heilig, R., Stahlberg, H., et al. (2016). GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. EMBO J. 35, 1766-1778. doi: 10.15252/embj.201694696
95. Schmid-Burgk, J. L., Chauhan, D., Schmidt, T., Ebert, T. S., Reinhardt, J., Endl, E., et al. (2016). A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291, 103-109. doi: 10.1074/jbc. C115.700492
96. Shah, M. S., and Brownlee, M. (2016). Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ. Res. 118, 1808-1829. doi: 10.1161/CIRCRESAHA.116.306923
97. Shahzad, K., Bock, F., Al-Dabet, M. M., Gadi, I., Kohli, S., Nazir, S., et al. (2016a). Caspase-1, but Not Caspase-3, promotes diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2270-2275. doi: 10.1681/ASN.2015060676
98. Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., et al. (2015). Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 87, 74-84. doi: 10.1038/ki.2014.271
99. Shahzad, K., Bock, F., Al-Dabet, M. M., Gadi, I., Nazir, S., Wang, H., et al. (2016b). Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy. Sci. Rep. 6:34228. doi: 10.1038/srep34228
100. Sharma, H., Pathan, R. A., Kumar, V., Javed, S., and Bhandari, U. (2011). Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int. J. Cardiol. 150, 193-200. doi: 10.1016/j.ijcard.2010.04.008
101. Sheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. B., et al. (2013). CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14, 812-820. doi: 10.1038/ni.2639
102. Shi, H., Wang, Y., Li, X., Zhan, X., Tang, M., Fina, M., et al. (2016). NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250-258. doi: 10.1038/ni.3333
103. Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., et al. (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660-665. doi: 10.1038/nature15514
104. Shi, X., Xie, W. L., Kong, W. W., Chen, D., and Qu, P. (2015). Expression of the NLRP3 Inflammasome in Carotid Atherosclerosis. J. Stroke Cerebrovasc. Dis. 24, 2455-2466. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.024
105. Singh, L. P. (2014). The NLRP3 inflammasome and diabetic cardiomyopathy: editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al. Cardiovasc. Drugs Ther. 28, 5-6. doi: 10.1007/s10557-013-6501-x
106. Stienstra, R., Joosten, L. A. B., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A. A., et al. (2010). The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605. doi: 10.1016/j.cmet.2010.11.011
107. Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L., Perera, D., et al. (2011). Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 108, 15324-15329. doi: 10.1073/pnas.1100255108
108. Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. (2013). Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 715, 246-255. doi: 10.1016/j.ejphar.2013.05.014
109. Tate, M., Grieve, D. J., and Ritchie, R. H. (2017). Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin. Sci. 131, 897-915. doi: 10.1042/CS20160491
110. Tate, M., Robinson, E., Green, B. D., McDermott, B. J., and Grieve, D. J. (2016). Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res. Cardiol. 111:1. doi: 10.1007/s00395-015-0518-1
111. Tenenbaum, A., and Fisman, E. Z. (2017). Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner? Cardiovasc. Diabetol. 16:91. doi: 10.1186/s12933-017-0573-z
112. Turner, N. A. (2016). Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J. Mol. Cell. Cardiol. 94, 189-200. doi: 10.1016/j.yjmcc.2015.11.002
113. Usui, F., Shirasuna, K., Kimura, H., Tatsumi, K., Kawashima, A., Karasawa, T., et al. (2015). Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 35, 127-136. doi: 10.1161/ATVBAHA.114.303763
114. Vallejo, S., Palacios, E., Romacho, T., Villalobos, L., Peiro, C., and Sanchez-Ferrer, C. F. (2014). The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc. Diabetol. 13:158. doi: 10.1186/s12933-014-0158-z
115. van den Borne, S. W., Diez, J., Blankesteijn, W. M., Verjans, J., Hofstra, L., and Narula, J. (2010). Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 30-37. doi: 10.1038/nrcardio.2009.199
116. Van Linthout, S., Riad, A., Dhayat, N., Spillmann, F., Du, J., Dhayat, S., et al. (2007). Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50, 1977-1986. doi: 10.1007/s00125-007-0719-8
117. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., et al. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188. doi: 10.1038/nm.2279
118. Vince, J. E., and Silke, J. (2016). The intersection of cell death and inflammasome activation. Cell. Mol. Life Sci. 73, 2349-2367. doi: 10.1007/s00018-016-2205-2
119. Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., et al. (2015). Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 467, 1881-1898. doi: 10.1007/s00424-014-1619-7
120. Wada, J., and Makino, H. (2013). Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. 124, 139-152. doi: 10.1042/CS20120198
121. Wang, S., Li, Y., Fan, J., Zhang, X., Luan, J., Bian, Q., et al. (2017). Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation. Cell Death Dis. 8:e2937. doi: 10.1038/cddis.2017.292
122. Wang, Y., Yu, B., Wang, L., Yang, M., Xia, Z., Wei, W., et al. (2017). Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus. PLoS ONE 12:e0181248. doi: 10.1371/journal.pone.0181248
123. Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T., et al. (2011). Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408-415. doi: 10.1038/ni.2022
124. Wilding, J. P. H. (2018). Medication use for the treatment of diabetes in obese individuals. Diabetologia 61, 265-272. doi: 10.1007/s00125-017-4288-1
125. Xiao, H., Lu, M., Lin, T. Y., Chen, Z., Chen, G., Wang, W. C., et al. (2013). Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 128, 632-642. doi: 10.1161/CIRCULATIONAHA.113.002714
126. Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R., and Birnbaum, Y. (2017). SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119-132. doi: 10.1007/s10557-017-6725-2
127. Yi, H., Peng, R., Zhang, L. Y., Sun, Y., Peng, H. M., Liu, H. D., et al. (2017). LincRNA-Gm4419 knockdown ameliorates NF-kappaB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell Death Dis. 8:e2583. doi: 10.1038/cddis.2016.451
128. Youm, Y. H., Adijiang, A., Vandanmagsar, B., Burk, D., Ravussin, A., and Dixit, V. D. (2011). Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 152, 4039-4045. doi: 10.1210/en.2011-1326
129. Younis, A., Eskenazi, D., Goldkorn, R., Leor, J., Naftali-Shani, N., Fisman, E. Z., et al. (2017). The addition of vildagliptin to metformin prevents the elevation of interleukin 1ss in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovasc. Diabetol. 16:69 doi: 10.1186/s12933-017-0551-5
130. Yu, C. H., Moecking, J., Geyer, M., and Masters, S. L. (2018). Mechanisms of NLRP1-mediated autoinflammatory disease in humans and mice. J. Mol. Biol. 430, 142-152. doi: 10.1016/j.jmb.2017.07.012
131. Zhang, W. B., Du, Q. J., Li, H., Sun, A. J., Qiu, Z. H., Wu, C. N., et al. (2012). The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats. J. Cell. Mol. Med. 16, 2227-2237. doi: 10.1111/j.1582-4934.2012.01536.x
132. Zhao, C., Gillette, D. D., Li, X., Zhang, Z., and Wen, H. (2014). Nuclear factor E2-related factor-2 (Nrf2) is required for NLRP3 and AIM2 inflammasome activation. J. Biol. Chem. 289, 17020-17029. doi: 10.1074/jbc. M114.563114
133. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128. doi: 10.1056/NEJMoa1504720
134. Zirlik, A., Abdullah, S. M., Gerdes, N., MacFarlane, L., Schonbeck, U., Khera, A., et al. (2007). Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 2043-2049. doi: 10.1161/ATVBAHA.107.149484
135. Zorrilla, E. P., Sanchez-Alavez, M., Sugama, S., Brennan, M., Fernandez, R., Bartfai, T., et al. (2007). Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl. Acad. Sci. U.S.A. 104, 11097-11102. doi: 10.1073/pnas.0611523104